Abstract:Objective·To construct an mRNA vaccine encoding hemagglutinin (HA) of influenza A H1N1 virus, and explore the protective effects of different booster vaccination strategies.Methods·Firefly luciferase (Fluc) was used as the reporter gene to construct Fluc mRNA vaccine enveloped in lipid nanoparticles (LNP). The in vivo expression of Fluc mRNA-LNP after intramuscular injection was determined by live imaging assay in mice. Furthermore, M15-HA mRNA-LNP derived from H1N1 subtype (A/Michigan/45/2015) was constructed. Mice were immunized with 20, 10, 5, or 1 µg doses of M15-HA mRNA-LNP twice (with an interval of 3 weeks) through intramuscular injection. Serum antibody titers were measured by enzyme-linked immunosorbent assay (ELISA) at 2 weeks and 4 weeks after the second immunization, and functional antibody levels were detected by hemagglutination inhibition test. The third booster vaccination was performed 40 d after the second immunization in 1 µg dose group with 1 µg M15-HA mRNA-LNP or 10 µg HA subunit vaccine. The levels of specific antibody and functional antibody were detected by ELISA and hemagglutination inhibition test, respectively 2 weeks and 4 weeks later.Results·Live imaging assay showed that luciferase activity could be detected in mice 1 d after injection of Fluc mRNA-LNP. At 2 weeks and 4 weeks after the second immunization of M15-HA mRNA-LNP, HA-specific antibodies were significantly higher than those before the immunization in all vaccination groups at different doses (P=0.000). The hemagglutination inhibition test showed that the levels of functional antibodies in the 20 μg dose and 10 μg dose groups were significantly higher than those in the PBS control group (P<0.05). After 1 µg dose group mice were immunized with HA protein or M15-HA mRNA-LNP, higher levels of HA-specific antibody and functional antibody were induced and maintained for a long time. There was no significant difference between the two different booster immunization strategies.Conclusion·M15-HA mRNA-LNP vaccine is constructed with immunogenicity and antibody neutralization activity. Low-dose mRNA priming vaccination followed by both homologous mRNA vaccine and heterologous protein subunit vaccine booster vaccination can induce stronger immune recall responses.

Study on immunogenicity of recombinant lentivirus expressing trimeric HA of swine H1 N1 influenza virus

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

Immune Responses and Protection Efficacy of a Recombinant Swinepox Virus Expressing HA1 Against Swine H3N2 Influenza Virus in Mice and Pigs.

Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).

Immune Efficacy of the Recombinant Plasmids Expressing HA Gene of H1N1 and H3N2 Subtype SIV in Mice

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Characterization of Monoclonal Antibodies Against Ha Protein of H1n1 Swine Influenza Virus and Protective Efficacy Against H1 Viruses in Mice

Characterization of immune response in mice induced by recombinant vaccinia virus(Tiantan) based multivalent H5N1 avian influenza vaccines

Response of BALB/c Mice to a Monovalent Influenza A （H1N1） 2009 Split Vaccine

Immunogenicity and Protective Efficacy of a Live Attenuated Vaccine Against the 2009 Pandemic A H1N1 in Mice and Ferrets.

Oral or Intranasal Immunization with Recombinant Lactobacillus Plantarum Displaying Head Domain of Swine Influenza A Virus Hemagglutinin Protects Mice from H1N1 Virus

Immune Responses and Protective Efficacy of A Recombinant Swinepox Virus Co-Expressing Ha1 Genes of H3n2 and H1n1 Swine Influenza Virus in Mice and Pigs

Protection Against Influenza H7n9 Virus Challenge with A Recombinant Np-M1-Hsp60 Protein Vaccine Construct in Balb/C Mice

Packaging of recombinant lentivirus expressing trimeric HA of swine H1N1 influenza virus

Intranasal Immunization With Recombinant Ha And Mast Cell Activator C48/80 Elicits Protective Immunity Against 2009 Pandemic H1n1 Influenza In Mice

Construction of an mRNA vaccine encoding hemagglutinin of influenza A H1N1 virus and investigation on booster immunization strategy

Immune Evaluation of Recombinant Lactobacillus Plantarum with Surface Display of HA1-DCpep in Mice.

Immune Efficacy of the Recombination Plasmids Expressing HA Gene of H3N2 Subtybe SIV in Mice

Evaluation of Oral Immunization with Recombinant Avian Influenza Virus Ha1 Displayed on the Lactococcus Lactis Surface and Combined with the Mucosal Adjuvant Cholera Toxin Subunit B

Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1.

Effectiveness on Humoral and Cellular Immunity of Attenuated and Inactivated Swine Influenza Viruses